The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
 
Gordan Srkalovic
Speakers' Bureau - EUSA Pharma; Foundation Medicine; Johnson & Johnson
 
Michael Rothe
No Relationships to Disclose
 
Pam K. Mangat
No Relationships to Disclose
 
Elizabeth Garrett-Mayer
No Relationships to Disclose
 
Eugene R Ahn
Employment - Cancer Treament Centers of America
Leadership - Cancer Treament Centers of America
 
Gregory Brouse
No Relationships to Disclose
 
John K Chan
Honoraria - AstraZeneca; Eisai; Genmab/Seagen; GlaxoSmithKline/Tesaro; Merck; Myriad Genetics
Consulting or Advisory Role - Agenus; AstraZeneca; Eisai; Immunogen; Mersana; Myriad Genetics; Roche/Genentech; Seagen; Tesaro/GSK
Speakers' Bureau - AstraZeneca; Genmab/Seagen; GlaxoSmithKline/Tesaro; Myriad Genetics
Travel, Accommodations, Expenses - AstraZeneca; Genmab/Seagen; GlaxoSmithKline; Myriad Genetics
 
Inderjit Mehmi
Speakers' Bureau - Bristol-Myers Squibb
 
Maya Khalil
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Company (Inst); Cantargia AB (Inst); Caris Life Sciences (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Janssen (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Lucence (Inst); National Cancer Institute (Inst); Nitto BioPharma (Inst); Numab (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst)
 
Herbert Leon Duvivier
Speakers' Bureau - AstraZeneca; Guardant Health; Regeneron
 
Anu G. Gaba
Research Funding - Caris Life Sciences (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Tempus (Inst)
 
Harshraj Leuva
Stock and Other Ownership Interests - AstraZeneca/Merck
 
Ramya Thota
No Relationships to Disclose
 
Kathleen J Yost
Stock and Other Ownership Interests - Pfizer (I)
Research Funding - Pfizer
Other Relationship - AstraZeneca; Natera; Pfizer
 
Gina N. Grantham
No Relationships to Disclose
 
Abigail Gregory
Employment - Biohaven Pharmaceuticals (I); Pfizer (I)
Stock and Other Ownership Interests - Biohaven Pharmaceuticals (I)
 
Dominique C. Hinshaw
No Relationships to Disclose
 
Susan Halabi
Employment - ASCO
Honoraria - AVEO; Bristol-Myers Squibb; Janssen; Sanofi
 
Richard L. Schilsky
Leadership - Clarified Precision Medicine; Leap Therapeutics
Stock and Other Ownership Interests - EQRx
Consulting or Advisory Role - Bryologyx; Cellworks; EQRx; Illumina; Scandion Oncology; Syapse; Zephyr AI
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)